Exact hopes to boost colorectal cancer test sensitivity
This article was originally published in Clinica
Executive Summary
In what could improve the sensitivity of its PreGen-Plus DNA-based stool assay for colorectal cancer, Exact Sciences has amended its exclusive licensing agreement with the Johns Hopkins University to add to the test a gene that has been strongly linked with the disease.